Article Per Year (5 Year)
p-Index From 2019 - 2024
0.61
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Kesehatan Indonesia
Fauzar Fauzar
Fakultas Kedokteran Universitas Andalas
Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Kajian Terkini CoronaVirus Disease 2019 (COVID-19) Chicy Widya Morfi; Ahmad Junaidi; Elsesmita Elsesmita; Diana Nur Asrini; Dya Mulya Lestari; Irvan Medison; Russilawati Russilawati; Fauzar Fauzar; Roza Kurniati; Finny Fitry Yani
Jurnal Ilmu Kesehatan Indonesia Vol 1 No 1 (2020): Maret 2020
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (482.016 KB) | DOI: 10.25077/jikesi.v1i1.13

Abstract

The COVID-19 outbreak in Wuhan, Hubei Province, China, caused by a newly known coronavirus strain, SARS-CoV-2, up to March 3th, 2020, has caused 90.870 confirmed cases to be reported from 72 countries (including Indonesia) with 3.112 deaths (CFR 3,4%). Upper airway swab and lower airway aspirate specimens from suspected patients are required for examination by the RT-PCR microbiological method for establishing COVID-19. There are no specific antivirals for the management of COVID-19. On January, 30th, 2020 WHO has established Covid-19 as the Public Health Emergency of International Concern (PHEIC), but the increase in the number of cases is fast enough so that on March,11th 2020, WHO has established Covid-19 as a pandemic.
COVID-19 dengan Komorbid Tuberkulosis Paru dan Diabetes Melitus Muthia Faurin; Fauzar Fauzar; Roza Kurniati; Alexander Kam; Eva Decroli
Jurnal Ilmu Kesehatan Indonesia Vol 1 No 3 (2020): November 2020
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1149.558 KB) | DOI: 10.25077/jikesi.v1i3.466

Abstract

A 61-year-old man was admitted a confirmed COVID-19 with comorbid pulmonary tuberculosis and type 2 diabetes mellitus. The patient was given favipiravir therapy, category 1 of antituberculosis drug, and insulin therapy. The patient responded well to therapy with improved clinical and laboratory indicators. Key words: COVID-19, pulmonary tuberculosis, diabetes mellitus
Terapi Controller pada Asma Alexander Kam; Fauzar Fauzar; Roza Kurniati; Zulkarnain Arsyad
Jurnal Ilmu Kesehatan Indonesia Vol 1 No 3 (2020): November 2020
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1306.388 KB) | DOI: 10.25077/jikesi.v1i3.467

Abstract

Asthma, according to the National Heart Lung and Blood Institute (NHBLI) in 2002, is a chronic inflammatory disorder of the airways that involves the role of many cells and cellular components. The long-term goals of asthma management are to achieve good symptom control and maintain normal living activities and to minimize the risk of exacerbations, airway obstruction, and side effects. The drugs available for asthma therapy are divided into long-term control or controller medication and rapid-acting or reliever medication based on their pharmacodynamics and clinical effects. Controller is a therapy given to reduce chronic airway inflammation, control symptoms, and reduce the risk of exacerbations and decreased lung function. There are several asthma controller drug options that have their respective advantages and disadvantages. Selection of the right controller will provide good asthma control. Keyword: Ashtma, therapy, controller
Co-Authors Ahmad Junaidi Alexander Kam Chicy WIdya Morfi Diana Nur Asrini Dya Mulya Lestari Elsesmita Elsesmita Eva Decroli Finny Fitry Yani Irvan Medison Muthia Faurin Roza Kurniati Russilawati, Russilawati Zulkarnain Arsyad